Petros Pharmaceuticals Demonstrates Positive Results Following Successful Completion of Initial Cohort of Phase 2 Equivalent Self-Selection Study for STENDRA (avanafil) Rx-to-OTC Switch [Y...
Petros Pharmaceuticals, Inc. (PTPI)
Company Research
Source: Yahoo! Finance
STENDRA® working to become the first erectile dysfunction medication to successfully achieve OTC status NEW YORK, NY / ACCESSWIRE / January 17, 2024 Petros Pharmaceuticals, Inc. (NASDAQ:PTPI), a company focused on expanding consumer access to medication through over-the- counter (OTC) drug development programs, announces the successful completion of the initial cohort of a Phase 2 equivalent Self-Selection Study (SSS). The study demonstrated that more than 78% of subjects utilizing the technology assistive application correctly self-selected to use STENDRA (avanafil) compared to 56% of subjects who utilized the Drug Facts Label (DFL) alone. (Please see important safety information for STENDRA, below). "The success of this first part of our Phase 2 equivalent self-selection study paves the way for us to aggressively pursue a larger SSS cohort, for which we expect to have results by the end of 2024. We believe our current cash runway will be more than sufficient to complete Phase 2
Show less
Read more
Impact Snapshot
Event Time:
PTPI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PTPI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PTPI alerts
High impacting Petros Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
PTPI
News
- Petros Pharmaceuticals announces online distribution for lead ED product with Lemonaid Health [Yahoo! Finance]Yahoo! Finance
- Petros Pharmaceuticals Expands Online Distribution for Prescription STENDRA(R) (avanafil) Through New Agreement with Lemonaid Health [Yahoo! Finance]Yahoo! Finance
- Petros Pharmaceuticals Expands Online Distribution for Prescription STENDRA(R) (avanafil) Through New Agreement with Lemonaid HealthAccesswire
- Petros Pharmaceuticals Receives Positive Response from FDA Following Recent Demonstration of Technology Component in Pursuit of OTC Status for STENDRA(R) (avanafil) Accesswire
- Petros Pharmaceuticals Reports Positive Results in an Initial Cohort Two-Arm Self-Selection (Phase 2-Equivalent) Study for STENDRA(R) (avanafil) as it Pursues OTC StatusAccesswire
PTPI
Sec Filings
- 4/1/24 - Form 10-K
- 3/22/24 - Form 8-K
- 2/14/24 - Form SC
- PTPI's page on the SEC website